Immunofluorescence Assay Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Market Overview

The  Immunofluorescence Assay market studied was projected to grow with a CAGR of nearly 5.8% over the forecast period. The major factor attributing to the growth of the market is the increase in the incidence of large intestine diseases like intestinal cancer, diverticulitis, Crohn’s Disease, ulcerative colitis, and inflammatory bowel disease. According to the American Association for the Advancement of Science (AAAS), the number of people suffering from inflammatory bowel diseases is three times higher than previous estimates, with sufferers also at a higher risk of developing colorectal cancer, affecting over 3 million people across Europe. Furthermore, the growing popularity of drainable ostomy bags and increasing investments in product development is boosting the market growth. However, the gaining popularity of the alternative procedures is  the major drawback of the market growth

Scope of the Report

As per the scope of the report, immunofluorescence is the specific antigen and antibody reaction where the antibodies are labeled with a fluorescent dye and the antigen-antibody complex is visualized using a fluorescent microscope. This report is segmented by Procedure, by Type, By Application and by Geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Indirect Immunofluorescence Segment is Dominating the Immunofluorescence Assay Market.

• The advantages of indirect immunofluorescence are high sensitivity, easy to change signal color based on changing the second antibody which can get commercially. The labeled second antibodies are conveniently obtained. Secondary antibodies are relatively inexpensive compared to primary antibodies. Further cost savings may be made by using the same conjugated secondary antibody to detect different primary antibodies.
• Apart from the above-mentioned factors, other factors boosting the segment growth are increasing incidence of cancer and infectious diseases where these assays are used to diagnose. According to the World Health Organization, the global cancer burden is expected to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide developed cancer during their lifetime, and one in 8 men and one in 11 women die from the disease. Furthermore, the growing investments in research and development programs by the biotechnology companies is boosting the segment growth.

To understand key trends, Download Sample Report